Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Search
Search
Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Merck & Co.’s RSV Antibody Approved In US In Time To Compete With Blockbuster Beyfortus
CDC Sign-Off Expected In June, Orders To Follow In July
09 Jun 2025
•
By
Mandy Jackson
Both Enflonsia and Beyfortus likely will be available for infants during the 2025-2026 RSV season in the US
(Shutterstock)
More from Strategy
More from Scrip